Related Experiment Videos
Angiopeptin inhibits oncogene induction in rabbit aorta after balloon denudation
C Bauters1, E Van Belle, N Wernert
1Department of Cardiology, University of Lille, France.
Background:
Angiopeptin, a synthetic cyclic octapeptide analogue of somatostatin, reduces neointimal hyperplasia after balloon denudation of rabbit aorta if administered before injury. The aim of this study was to analyze the effect of angiopeptin pretreatment on the level of expression of the c-fos and c-jun protooncogenes, early markers of smooth muscle cell proliferation, after balloon denudation of rabbit aorta.
Methods And Results:
For histological analysis of the effect of angiopeptin on neointimal thickening after aortic balloon denudation, rabbits were randomized into three groups: group 1 (controls), twice-daily injections of saline begun 24 hours before balloon denudation (n = 9); group 2, twice-daily injections of angiopeptin 10 micrograms/kg begun 24 hours before balloon denudation (n = 9); and group 3, twice-daily injections of angiopeptin 10 micrograms/kg begun 1 hour after balloon denudation (n = 7). The degree of neointimal thickening 28 days after balloon denudation was significantly less in group 2 than in group 1 (neointimal area: group 1, 0.59 +/- 0.11 mm2; group 2, 0.22 +/- 0.05 mm2; P < .05. Neointima/media: group 1, 0.85 +/- 0.17; group 2, 0.23 +/- 0.05; P < .05). When angiopeptin was started 1 hour after denudation (group 3), however, the neointimal area (0.52 +/- 0.09 mm2) and the neointima/media ratio (0.76 +/- 0.10) were not statistically different from the control group. For analysis of protooncogene induction, rabbits received twice-daily subcutaneous injections of saline (n = 7), angiopeptin 10 micrograms/kg (n = 8), or angiopeptin 100 micrograms/kg (n = 4) begun 24 hours before balloon denudation. The animals were killed 30 minutes after balloon denudation, and total aortic RNA was hybridized with fos and jun probes. Expression of c-fos and c-jun was detected 30 minutes after injury; angiopeptin pretreatment at 20 micrograms.kg-1.d-1 induced a 41% reduction in c-fos expression and a 42% reduction in c-jun expression compared with control animals. The inhibitory effect at the higher dose of angiopeptin was similar.
Conclusions:
Our results show that the inhibitory effect of angiopeptin on neointimal thickening is related to events that occur very early after injury and suggest that the inhibition of smooth muscle cell activation may be responsible, at least in part, for this effect.
Insights
Angiopeptin pretreatment significantly reduces neointimal hyperplasia after arterial injury by inhibiting early gene expression. This suggests angiopeptin
Area of Science:
- Vascular Biology
- Molecular Medicine
- Pharmacology
Background:
- Angiopeptin, a somatostatin analogue, is known to reduce neointimal hyperplasia post-injury.
- Neointimal hyperplasia is a key factor in vascular restenosis.
- Early markers of smooth muscle cell proliferation include c-fos and c-jun protooncogenes.
Purpose of the Study:
- To investigate the effect of angiopeptin pretreatment on c-fos and c-jun protooncogene expression.
- To determine if angiopeptin's inhibitory effect on neointimal thickening is linked to early cellular events.
Main Methods:
- Rabbits underwent balloon denudation of the aorta and were randomized into control and angiopeptin treatment groups.
- Angiopeptin was administered either before or after balloon denudation.
- Histological analysis assessed neointimal thickening, and RNA hybridization measured c-fos and c-jun expression.
Main Results:
- Pretreatment with angiopeptin significantly reduced neointimal thickening compared to controls (P < .05).
- Angiopeptin administered after injury did not show a significant effect on neointimal thickening.
- Angiopeptin pretreatment reduced c-fos and c-jun expression by 41% and 42%, respectively, 30 minutes post-injury.
Conclusions:
- The inhibitory effect of angiopeptin on neointimal thickening is associated with early post-injury events.
- Inhibition of smooth muscle cell activation by angiopeptin may contribute to its therapeutic effect.
- Angiopeptin's efficacy is dependent on its administration timing relative to vascular injury.